Even though Dr Fisher was excelling in his chosen vocation, cardiovascular medicine, over time he lost his sense of purpose. Despite his success, he felt wounded and disconnected. His training predisposed him to suppress his emotions when faced with suffering and tragedy in order to be a better doctor. Today, Dr Fisher is at the forefront of the campaign to end clinician burnout.
This week’s guest on Parallax is Dr Jonathan Fisher Cardiologist and Organizational Well-Being and Resiliency Leader at Novant Health.
In this insightful and solution seeking episode, Dr Fisher shares how his journey to build a well-balanced relationship with his profession paved a way for his role as Organizational Well-Being and Resiliency Leader. Dr Kalra and Dr Fisher discuss the need for a more human faced medical education and an open dialogue about wellness and emotional wellbeing. They talk about interventions that can have huge impact on individuals and institutions alike.
What are the warning signs of burnout? How can institutions tackle systemic problems? What are some of the conversations that can help? What is Dr Fisher’s advice to our listeners?
Follow this link to learn more about Ending Clinician Burnout Global Community: https://endingphysicianburnout.com
Dr Ankur Kalra’s guests this week are Dr Martha Gulati, internationally recognized cardiologist specializing in Women and Heart Disease, Heart Disease Prevention and Dr Devesh Rai, first year cardiology fellow at Rochester General Hospital.
They discuss the importance of preventative medicine, their experience of reducing hypertension with non-pharmaceutical and pharmaceutical methods, and the significance of the integrated “team approach” when treating comorbid conditions such as hypertension. Athena also shares her thoughts on cardiologists’ responsibility to shape their patients’ lifestyle choices.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
Chest pain is one of the most common reasons for an emergency room visit in the US, with almost 6 million ER visits annually, yet there is no consensus on how to compare the results from various hscTn assays. Tune in to hear Santiago outline the advantages and limitations of using hscTn as a standard biomarket to evaluate patients with suspected ACS in the ER.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.